Addendum 2021 to Indian Pharmacopoeia 2018.JPG

 

In order to further strengthen the standards of the drugs being manufactured and/or marketed in India, IPC has come out with the publication of the Addendum 2021 to Indian Pharmacopoeia (IP) 2018. Sh. Rajesh Bhushan, Secretary-Health & Family Welfare, Govt. of India and Chairperson-Indian Pharmacopoeia Commission (IPC) released the IP Addendum 2021 on 31st March 2021 at Nirman Bhawan, New Delhi in presence of the officials of Ministry of Health & Family Welfare, Govt. of India, representatives of various Pharma Associations, and IPC officials.

Addendum 2021 to IP 2018 contains a total of 66 new drug monographs [including 59 Chemical, 05 Herbs & Herbal Products, and 02 Blood & Blood-Related Products] and 04 new General Chapters. In addition, a total of 260 monograph amendments have also been included in the content of the IP Addendum 2021 that would further upgrade the quality of drug standards included in the IP. The effective date of this Addendum has been kept as 1st October 2021 and a total period of six months is being given to the stakeholders to implement the new standards included therein.

On this occasion, Sh. Rajesh Bhushan appreciated the contributions of members of the Scientific Body of IPC, various Expert Working Groups of IP, and IPC scientists in bringing out this Addendum 2021. He further expressed that with the publication of IP Addendum 2021, IP will make a big contribution for overall strengthening of the drugs regulation in India.  

 

To know the Salient Features of Addendum 2021 to Indian Pharmacopoeia 2018 and its Effective Date (Please Click)

News & Highlights


View All

IPC Products

ip nfi
 
Connect with IPC